Incyte Earnings Preview: Can This Streak Continue?

Incyte (NASDAQ:INCY) will report earnings before markets open on Thursday, May 2nd. Incyte Corporation is using its expertise in genomics and medicinal chemistry, as well as molecular, cellular, and in vivo biology to discover and develop novel therapeutics. The Company has drug discovery programs underway focused on the identification of new small molecule drugs for cancer and inflammation.

Here is your Cheat Sheet to Incyte Earnings:

Earnings Expectations: Analysts expect earnings of $-0.20 per share on revenues of $68.16 million.

Analyst Trends:

Analysts have a more positive outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has risen from a loss of $0.05 to a loss $0.01. For the current year, the average estimate is a loss of $0.35, which is better than the estimate ninety days ago.

Earnings Trends:

Here’s how Incyte has been performing on an annual basis:

Fiscal Year 2008 2009 2010 2011 2012
Revenue ($) in millions 3.92 9.27 169.88 94.46 297.06
Diluted EPS ($) -1.99 -2.06 -0.26 -1.49 -0.34

Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:

Quarter Dec. 31, 2011 Mar. 31, 2012 Jun. 30, 2012 Sep. 30, 2012 Dec. 31, 2012
Revenue ($) in millions 28.89 36.18 86.54 60.49 113.85
Diluted EPS ($) -0.4358 -0.36 0.03 -0.17 0.1426

Past Performance:
Incyte has beat analyst estimates 4 times in the past four quarters. Shareholders could expect a boost if the company beats estimates.

“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at]